And Big Pharma’s not done cashing in on the weight-loss boom. Drugmakers are readying a new wave of next-level GLP-1 treatments, with several promising candidates in the pipeline. These experimental ...
The Food and Drug Administration is set to treat the application under its priority program to accelerate the review of ...
Novo Nordisk reported promising mid-stage results for its experimental obesity drug amycretin in diabetes patients on Tuesday ...
Novo Nordisk A/S’s next-generation diabetes shot lowered patients’ blood sugar and helped them lose weight in a study that may be a positive sign for the embattled drugmaker’s future portfolio.
Women who have rebound weight gain after stopping Wegovy or similar jabs end up gaining more weight during pregnancy, leading ...
When questioned about his recent medical history, the patient revealed that he had undergone bariatric (weight loss) surgery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results